{
    "5bd2bb3b-1a8d-3835-9ca7-6f1d82ac06f6": {
        "uuid": "5bd2bb3b-1a8d-3835-9ca7-6f1d82ac06f6",
        "title": "AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody\u00ae-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress",
        "publisher": "PR Newswire",
        "link": "https://finance.yahoo.com/news/abbvie-announces-breaking-results-phase-124500437.html",
        "providerPublishTime": 1654951500,
        "type": "STORY"
    },
    "df1e1011-8fd2-3b8b-bebb-acbb8512decc": {
        "uuid": "df1e1011-8fd2-3b8b-bebb-acbb8512decc",
        "title": "3 Dividend Stocks to Buy Now for 20 Years of Income Growth",
        "publisher": "InvestorPlace",
        "link": "https://finance.yahoo.com/news/3-dividend-stocks-buy-now-101109217.html",
        "providerPublishTime": 1654855869,
        "type": "STORY"
    },
    "c0488ddd-e2e4-36dc-9918-7fec48069c4b": {
        "uuid": "c0488ddd-e2e4-36dc-9918-7fec48069c4b",
        "title": "AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Na\u00efve Myelofibrosis Patients",
        "publisher": "PR Newswire",
        "link": "https://finance.yahoo.com/news/abbvie-presents-investigational-navitoclax-preliminary-071500232.html",
        "providerPublishTime": 1654845300,
        "type": "STORY"
    },
    "c1f96efd-354f-3114-adcc-eb04da4f85bd": {
        "uuid": "c1f96efd-354f-3114-adcc-eb04da4f85bd",
        "title": "New Data Demonstrates AbbVie's VENCLYXTO\u00ae/VENCLEXTA\u00ae Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment",
        "publisher": "PR Newswire",
        "link": "https://finance.yahoo.com/news/data-demonstrates-abbvies-venclyxto-venclexta-050500919.html",
        "providerPublishTime": 1654837500,
        "type": "STORY"
    },
    "cc8420fe-01f8-3e0b-85b4-85ff830fff37": {
        "uuid": "cc8420fe-01f8-3e0b-85b4-85ff830fff37",
        "title": "Is AbbVie Stock A Buy As Humira Biosimilar Rivals Loom?",
        "publisher": "Investor's Business Daily",
        "link": "https://finance.yahoo.com/m/cc8420fe-01f8-3e0b-85b4-85ff830fff37/is-abbvie-stock-a-buy-as.html",
        "providerPublishTime": 1654705815,
        "type": "STORY"
    },
    "73f1e984-608e-3d35-b7ab-29cc3c9bbb53": {
        "uuid": "73f1e984-608e-3d35-b7ab-29cc3c9bbb53",
        "title": "Could AbbVie Stock Help You Retire a Millionaire?",
        "publisher": "Motley Fool",
        "link": "https://finance.yahoo.com/m/73f1e984-608e-3d35-b7ab-29cc3c9bbb53/could-abbvie-stock-help-you.html",
        "providerPublishTime": 1654688700,
        "type": "STORY"
    },
    "4addb90b-8482-3db3-ab94-1275bf7013e3": {
        "uuid": "4addb90b-8482-3db3-ab94-1275bf7013e3",
        "title": "Warren Buffett Just Sold This Popular Stock -- Should You?",
        "publisher": "Motley Fool",
        "link": "https://finance.yahoo.com/m/4addb90b-8482-3db3-ab94-1275bf7013e3/warren-buffett-just-sold-this.html",
        "providerPublishTime": 1654616700,
        "type": "STORY"
    },
    "0e6782d2-4b6b-3dbe-bdba-250aee267959": {
        "uuid": "0e6782d2-4b6b-3dbe-bdba-250aee267959",
        "title": "Here's What This Drug News Could Mean for AbbVie's Shareholders",
        "publisher": "Motley Fool",
        "link": "https://finance.yahoo.com/m/0e6782d2-4b6b-3dbe-bdba-250aee267959/here%27s-what-this-drug-news.html",
        "providerPublishTime": 1654614000,
        "type": "STORY"
    }
}